NOV. 13–ALPINE, UTAH– Clifton Mining Co. has announced that American Biotech Labs, a company Clifton owns approximately 30 percent of, has finished the approval process with the U.S. Environmental Protection Agency EPA, and expects to get full hospital approval for its disinfectant, ASAP Solution, in the next few weeks.
In the test work for the EPA hospital approval, the ASAP Solution had to kill hundreds of thousands of some of the deadliest types of bacteria found in the United States within minutes, and the EPA says the solution proved able to do so. There were approximately 1,600 individual bacterial tests in just one series alone. American Biotech’s product was able to pass all the tests.
American Biotech Labs expects to get the full hospital disinfectant approval within the next 15 to 45 days. The approval will open the door to sell its effective, yet non-toxic disinfectant to thousands of hospitals, clinics, rest homes, and other healthcare facilities worldwide.
Management expects sales of the new disinfectant to possibly begin as soon as January
2003.
“This will be a very important product for the market. This product is non-toxic and yet highly effective at killing even the methicillin-resistant staphylococcus aureus (MRSA) super bacteria,” says Keith Moeller, vice president. “This product can be used in and around patients to kill bacteria with no adverse effect. It is so safe that it could be sprayed right on the skin or even consumed orally with no adverse consequences.”
Malaria and drug testing
A new human trial specifically testing ASAP’s effectiveness on malaria is under way in Ghana, West Africa. In the first two tests, 19 people who had been diagnosed with malaria were treated with the ASAP Solution. Doctors there says all 19 people, most of them children, fully recovered within just seven days.
With no reported failures, the human tests have gone so well that the official Food and Drug Board of Ghana has already approved the ASAP Solution for drug registration. Recent West African trials also tested the product as a treatment for fungal skin infections, vaginal infections, urinary tract infections, tonsilitis, pharingitis, some sexually transmitted diseases, conjunctivitis, upper respiratory tract infections, nasal and sinus problems, etc. In almost every human case tested so far, full recovery was reached in just 1-7 days.